Lichen planopilaris after imiquimod 5% cream for multiple BCC in basal cell naevus syndrome

Alessandra Drummond, Janine Pichler, Giuseppe Argenziano, Iris Zalaudek, Caterina Longo, Aimilios Lallas, Simonetta Piana, Elvira Moscarella

Research output: Contribution to journalArticlepeer-review


Basal cell naevus syndrome is an inherited autosomal dominant genetic disorder characterised by multiple basal cell carcinomas (BCC), skeletal, neurological and opthalmological abnormalities. The treatment of choice of the often multiple and large BCC consists of a combined approach including surgery, liquid nitrogen and other topical treatment modalities. Imiquimod 5% cream is an immune-response-modifying drug with antiviral and anti-tumour activity. Recent reports have associated the immune-stimulant properties of imiquimod with the exacerbation of several autoimmune skin diseases, such as eczema, psoriasis, vitiligo and lichenoid dermatitis. Here we report a patient with basal cell naevus syndrome who developed a lichen planopilaris on the same site of the scalp, which had been previously treated with two cycles of imiquimod for multiple BCC.

Original languageEnglish
Pages (from-to)e105-e107
JournalAustralasian Journal of Dermatology
Issue number4
Publication statusPublished - Nov 1 2015


  • Gorlin-Goltz
  • imiquimod 5%
  • lichen planopilaris

ASJC Scopus subject areas

  • Dermatology


Dive into the research topics of 'Lichen planopilaris after imiquimod 5% cream for multiple BCC in basal cell naevus syndrome'. Together they form a unique fingerprint.

Cite this